参麦注射液联合阿替普酶治疗急性心肌梗死的临床效果研究.

Objective: To investigate the clinical effect of Shenmai injection combined with batroxobin in the treatment of acute myocardial infarction. Methods: 98 cases of patients with acute myocardial infarction who were treated in our hospital from January 2015 to December 2016 were randomly divided into two groups. The control group was given intravenous alteplase 100 mg, 90 min infusion is completed, the first intravenous injection of 15 mg, and 50 mg intravenous infusion of alteplase in 30 min, finally intravenous infusion of35 mg in 60 min, once a day. The observation group was treated with intravenous injection of Shenmai injection, 100 mL each time, once a day. The clinical effects, changes of the left ventricular ejection fraction, left ventricular end diastolic diameter, left ventricular posterior wall thickness and other cardiac functions, serum TnI, CK-MB, SOD, ET-1 levels were detected and compared before and after half a year follow-up between two groups, the prognosis of two groups were observed and compared. Results: After treatment, the effective rate of observation group was 91.83%(45/49), which was significantly higher than that of the control group[71.43%(35/49)](P<0.05). The left ventricular ejection fraction, left ventricular end diastolic diameter, and left posterior wall thickness of both groups were significantly improved after treatment(P<0.05), which improved better than those of the control group(P<0.05). After treatment, the serum levels of Tn I, CK-MB and ET-1 of both groups were significantly lower than those before treatment(P<0.05), and the serum levels of SOD were significantly increased(P<0.05), which improved more obviously in the observation group than those of control group(P<0.05). The incidence of reinfarction, post infarction angina pectoris and coronary thrombosis of observation group were lower than those of the control group(P<0.05), and the incidence of recanalization was significantly higher than that of the control group(P<0.05). Conclusions:The clinical effect and safety of Shenmai injection combined with batroxobin in the treatment of acute myocardial infarction weer better than batroxobin alone. [ABSTRACT FROM AUTHOR]